Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-037613
Filing Date
2025-02-27
Accepted
2025-02-27 07:33:44
Documents
16
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 d934878ds8.htm S-8 39505
2 EX-5.1 d934878dex51.htm EX-5.1 7377
3 EX-23.1 d934878dex231.htm EX-23.1 2099
4 EX-FILING FEES d934878dexfilingfees.htm   iXBRL EX-FILING FEES 30689
5 GRAPHIC g934878g0207065157576.jpg GRAPHIC 2661
  Complete submission text file 0001193125-25-037613.txt   233483

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT d934878dexfilingfees_htm.xml XML 13587
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285308 | Film No.: 25673046
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)